Skip to Main Content (Press Enter)

Logo UNISS
  • ×
  • Home
  • Degrees
  • Courses
  • Jobs
  • People
  • Outputs
  • Organizations
  • Third Mission
  • Expertise & Skills
  • Equipment

Logo UNISS

|

UNIFIND

uniss.it
  • ×
  • Home
  • Degrees
  • Courses
  • Jobs
  • People
  • Outputs
  • Organizations
  • Third Mission
  • Expertise & Skills
  • Equipment
  1. Outputs

Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study.

Academic Article
Publication Date:
2014
Short description:
Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study / Arru, G., Leoni, S., Pugliatti, M., Mei, A., Serra, C., Delogu, L.G., Manetti, R., Dolei, A., Sotgiu, S., Mameli, G.. - In: MULTIPLE SCLEROSIS. - ISSN 1352-4585. - Feb;20(2):174-82:2(2014), pp. 174-182. [10.1177/1352458513494957]
abstract:
Abstract

BACKGROUND:

Several viruses were reported as co-factors triggering the pathogenesis of multiple sclerosis (MS), including the endogenous retroviruses of the HERV-W family, that were also proposed as biomarkers of disease progression and therapy outcome.

OBJECTIVE:

The objective of this article is to clarify whether in MS patients treatment with natalizumab has effects on MSRV/syncytin-1/HERV-W expression and the possible relationship with disease outcome.

METHODS:

Peripheral blood mononuclear cells were collected from 22 patients with relapsing-remitting disease, at entry and after three, six and 12 months of treatment with natalizumab. The cell subpopulations and the expression of MSRVenv/syncytin-1/HERV-Wenv were analyzed by flow cytometry and by discriminatory env-specific RT-PCR assays.

RESULTS:

By flow cytometry the relative amounts of T, NK and monocyte subpopulations were shown to remain fairly constant. A relative increase of B lymphocytes was observed at three to six months (p = 0.033). The MSRVenv and syncitin-1 transcripts were reduced at six to 12 months of therapy (p = 0.0001). Accordingly, at month 12, the plasma-membrane levels of the HERV-Wenv protein were reduced (p = 0.0001). B cells, NK and monocytes but not T cells expressed the HERV-Wenv protein. None of the patients relapsed during therapy.

CONCLUSION:

Effective therapy with natalizumab downregulates MSRV/syncytin-1/HERV-W expression.
Iris type:
1.1 Articolo in rivista
Keywords:
natalizumab; multiple sclerosis therapy; MSRV/syncytin-1/HERV-W expression
List of contributors:
Arru, Giannina; Leoni, S; Pugliatti, M; Mei, A; Serra, Caterina; Delogu, Lucia Gemma; Manetti, Roberto; Dolei, Antonina; Sotgiu, Stefano; Mameli, Giuseppe
Authors of the University:
MANETTI Roberto
SOTGIU Stefano
Handle:
https://iris.uniss.it/handle/11388/60159
Published in:
MULTIPLE SCLEROSIS
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.1.0